As Cipla turns 90, the pharmaceutical giant is reimagining itself as a brand fit for a wellness-driven, digital-first India.

In the second part of his Pharma Commerce video interview, Hyung Heon Kim, CEO of MetaVia, explains how dual-action metabolic therapies can address clinical or tolerability gaps observed in ...

Copycats and false advertisements are also to blame for the increased threats. Stemming from social media testimonials all ...

US - FTC Uses Its Consumer Protection Powers To Regulate Sellers Of GLP-1s. Legal News and Analysis - USA - Conventus Law ...

Experts say there’s no evidence GLP-1s can be absorbed through the skin — and these patches don’t contain the FDA-approved ...

Menopausal hormone treatment (MHT) might indirectly help with weight loss by improving sleep and redistributing abdominal fat ...

Some people are discovering that being thinner can sometimes mean looking older. Local cosmetic surgeons weigh-in with ...

More than one-third of people who helped develop the 2023 guidelines for treating children with obesity had undisclosed ...

In today's Morning Rounds newsletter: a failed long Covid drug may get another shot, the benefits of even a little activity ...

Novo Nordisk sees 65% obesity drug sales growth, forecasts $8.14–$9.59B FY25 free cash flow. Click here to read an analysis ...

Low rates of retained gastric contents were seen in endoscopy patients on GLP-1 receptor agonists ( RAs), a retrospective ...

Patients with idiopathic intracranial hypertension who use a GLP-1 receptor agonist are less likely to experience symptoms, require medications, or undergo surgery.